GlassScriptPhysician profile
Emily L Newlin
NPI 1265086565
$3,939.18
in general payments reported to CMS, 2019-2025
22 companies · $2,109 in 2025
The $2,109 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $105 · 2024: $1,726 · 2025: $2,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,930 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,929.94 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,429.19 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $604.81 | 2023-2025 | |
| Genzyme Corporation | $389.48 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $331.06 | 2024-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $205.62 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $148.00 | 2023-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $139.10 | 2023-2025 | Rebyota |
| Pfizer INC. | $128.09 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.81 | 2025 | Xifaxan |
| Gilead Sciences, INC. | $83.20 | 2024-2025 | |
| Ardelyx, INC. | $70.26 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $66.46 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $55.16 | 2024-2025 | Vowst, Zenpep |
| Neuraxis, INC. | $49.37 | 2025 | |
| Ironwood Pharmaceuticals, INC | $36.56 | 2023-2024 | Linzess |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $34.82 | 2024-2025 | Suflave, Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.70 | 2024 | Cyltezo |
| Lilly USA, LLC | $18.24 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $15.83 | 2025 | Iqirvo |
| Echosens North America, INC. | $14.96 | 2024 | Fibroscan |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 | |
| Janssen Scientific Affairs, LLC | $4.22 | 2024 | Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Newlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.